REG - Physiomics PLC - Launch of Website for Requisitioned Meeting

PhysiomicsAnnouncement

22/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260422:nRSV3905Ba&default-theme=true

RNS Number : 3905B  Physiomics PLC  22 April 2026

22 April 2026

 

Physiomics plc

("Physiomics" or the "Company")

 

Launch of Website for Requisitioned Meeting

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, announces the launch of a dedicated website
aimed at providing key information to shareholders considering their vote in
relation to the Company's forthcoming Requisitioned General Meeting to be held
at 10.00 a.m. on 29 April 2026 ("Requisitioned General Meeting").

 

The website is available at www.pycrequisition.co.uk
(http://www.pycrequisition.co.uk) and has been created to ensure that all
shareholders have access to transparent, accurate, and relevant information as
they prepare for the upcoming shareholder vote. The site includes:

 

·    Circular containing information on the requisition;

·    Board's position regarding the requisition;

·    Board's recommendations to shareholders; and

·    Details of how to vote and key deadlines.

 

Physiomics is committed to maintaining open and constructive engagement with
its shareholders and the launch of this dedicated website forms part of the
Company's broader efforts to ensure shareholders can make informed decisions.

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk)

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep
biology expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all
relevant and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and clinical
studies. Through use of cutting-edge computational
tools, bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 140 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics &
CRUK.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGZDMMNGVZZ



            Copyright 2019 Regulatory News Service, all rights reserved